← Back to Screener
Actinium Pharmaceuticals, Inc (ATNM)
Price$1.44
Favorite Metrics
Price vs S&P 500 (26W)-21.50%
Price vs S&P 500 (4W)7.62%
Market Capitalization$42.98M
All Metrics
Book Value / Share (Quarterly)$0.25
P/TBV (Annual)1.76x
Revenue Growth (3Y)-55.63%
Cash Flow / Share (Quarterly)$-0.79
Price vs S&P 500 (YTD)-8.55%
Net Profit Margin (TTM)-5701.11%
EPS (TTM)$-1.09
10-Day Avg Trading Volume0.21M
EPS Excl Extra (TTM)$-1.09
EPS (Annual)$-1.09
ROI (Annual)-431.96%
Net Profit Margin (5Y Avg)-5775.48%
Cash / Share (Quarterly)$1.54
ROA (Last FY)-65.45%
Revenue Growth TTM (YoY)11.11%
EBITD / Share (TTM)$-1.16
ROE (5Y Avg)-153.37%
Operating Margin (TTM)-6324.44%
Cash Flow / Share (Annual)$-0.79
P/B Ratio5.49x
P/B Ratio (Quarterly)5.42x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)-55.59x
Net Interest Coverage (TTM)-10.19x
ROA (TTM)-56.57%
EPS Incl Extra (Annual)$-1.09
Current Ratio (Annual)6.20x
Quick Ratio (Quarterly)6.02x
3-Month Avg Trading Volume0.14M
52-Week Price Return4.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.59
P/S Ratio (Annual)477.60x
Asset Turnover (Annual)0.00x
52-Week High$1.95
Operating Margin (5Y Avg)-5858.31%
EPS Excl Extra (Annual)$-1.09
CapEx CAGR (5Y)-16.29%
Tangible BV CAGR (5Y)37.21%
26-Week Price Return-12.75%
Quick Ratio (Annual)6.02x
13-Week Price Return-2.26%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.20x
Enterprise Value$-5.003
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-40.95%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-37652.22%
Cash / Share (Annual)$1.54
3-Month Return Std Dev63.67%
Net Income / Employee (TTM)$-1
ROE (Last FY)-432.56%
Net Interest Coverage (Annual)-30.00x
EPS Basic Excl Extra (Annual)$-1.09
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.09
ROI (TTM)-204.19%
P/S Ratio (TTM)477.60x
Pretax Margin (5Y Avg)-5775.48%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.59
Price vs S&P 500 (52W)-31.09%
Year-to-Date Return-4.41%
5-Day Price Return17.12%
EPS Normalized (Annual)$-1.09
ROA (5Y Avg)-46.97%
Net Profit Margin (Annual)-37652.22%
Month-to-Date Return30.61%
Cash Flow / Share (TTM)$-1.89
EBITD / Share (Annual)$-1.16
Operating Margin (Annual)-40274.44%
ROI (5Y Avg)-153.21%
EPS Basic Excl Extra (TTM)$-1.09
P/TBV (Quarterly)2.69x
P/B Ratio (Annual)5.42x
Pretax Margin (TTM)-5701.11%
Book Value / Share (Annual)$0.25
Price vs S&P 500 (13W)-5.12%
Beta0.02x
P/FCF (Annual)5.19x
Revenue / Share (TTM)$0.00
ROE (TTM)-204.37%
52-Week Low$0.95
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.09
4.09
4.09
4.09
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ATNMActinium Pharmaceuticals, Inc | 477.60x | 11.11% | — | — | $1.44 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Actinium Pharmaceuticals develops targeted radiotherapies for hard-to-treat cancers using monoclonal antibodies to deliver radioisotopes directly to cancer cells. The company's portfolio includes Iomab-B for hematopoietic stem cell transplantation and Actimab-A, in clinical trials for acute myeloid leukemia. This platform approach addresses cancers with limited existing treatment options.